Drug
Nepafenac clinical trials
Also written Nevanac.
- studies test it
- 46
- open now
- 1
- in phase 3
- 9
- first study started
- 2005
Keep track of what changes. Save the nepafenac studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Nevanac
- 15
Combined with it in one product
Studies by the year they started
45 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 7
- Phase 3
- 9
- Phase 4
- 22
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
- Cataract
- 19
Who runs them
Industry 13 · Other 33
Alcon Research (10) · University Hospital of Patras (2) · Frank A. Bucci, Jr., M.D. (2) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Muhammad Aamir Latif (1) · Ankara Yildirim Beyazıt University (1) · Pomeranian Medical University Szczecin (1) · Indonesia University (1)
Often tested with
Tested in the same studies.
Ketorolac (10) · Bromfenac (8) · Diclofenac (3) · Ketorolac Tromethamine (3) · Lubricant (1) · Triamcinolone (1) · Indomethacin (1) · Difluprednate (1)
Studies
Open first, then newest update. How each study uses nepafenac is read from its arms, and is right about nine times in ten.
Testing it · 46
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract SurgeryRecruitingNot applicableNemocnice KolínNCT07178639Written as Nepafenac 0.3% Oph Susp
- Comparison Between Low-Dose and High-Dose Nepafenac SodiumCompletedNot applicableMuhammad Aamir LatifNCT07749027Written as Nepafenac sodium (High-dose )
- Perioperative Topical Nepafenac After Epiretinal Membrane SurgeryCompletedPhase 4Ankara Yildirim Beyazıt UniversityNCT07736690Written as Nepafenac 0.1% Ophthalmic Suspension
- Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract PhacoemulsificationCompletedPhase 4Pomeranian Medical University SzczecinNCT07696104Written as Nepafenac 0.1% eyedrops
- A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum StenosisActive, not recruitingPhase 4Instituto de Oftalmología Fundación Conde de ValencianaNCT07372014Written as Nepafenac and lubricant
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative VitreoretinopathyCompletedPhase 4Indonesia UniversityNCT07162818Written as Nepafenac 0.1% eyedrops
- NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)CompletedPhase 2Jaeb Center for Health ResearchNCT01331005Written as nepafenac 0.1% drops
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal PhotocoagulationTerminatedPhase 2Asociación para Evitar la Ceguera en MéxicoNCT00801905Written as Nepafenac
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye DropsStatus unknownPhase 2L.V. Prasad Eye InstituteNCT04843839Written as Nepafenac 0.1% Oph Susp
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic SuspensionCompletedPhase 3Actavis Inc.NCT03499873Written as Nepafenac 0.3% Oph Susp
- Macular Edema Nepafenac vs. Difluprednate Uveitis TrialTerminatedPhase 4University of California, San FranciscoNCT01939691Written as Nepafenac
- Post Intravitreal Injection Topical NSAID vs. PatchingStatus unknownPhase 4The New York Eye & Ear InfirmaryNCT03918590Written as nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
- Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical TrialCompletedPhase 4Silverstein Eye CentersNCT03886779Written as Nepafenac
- Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus PlaceboCompletedNot applicableIntuor Technologies, Inc.NCT03025945Written as Nepafenac 0.3%
- PGE2 Levels in Patient Treated With NSAIDsCompletedPhase 3University of TriesteNCT03597867Written as Nevanac
- Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral IridotomyStatus unknownNot applicableSheba Medical CenterNCT02955641Written as Nepafenac 0.1%
- Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal InjectionsCompletedNot applicableUniversity Hospital of PatrasNCT03406689Written as Nepafenac 0.1% Oph Susp
- Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular EdemaCompletedPhase 3Federal University of São PauloNCT00780780Written as Triamcinolone + Nepafenac
- Dropless vs. Standard Drops Contralateral Eye StudyCompletedPhase 4Carolina Eyecare Physicians, LLCNCT02515045Written as Ilevro
- Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal InjectionsCompletedNot applicableUniversity Hospital of PatrasNCT02821390Written as Nepafenac Eye Drops
See all 46 studies that test nepafenac →
As the comparator · 2 — what is tested is compared with nepafenac
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%CompletedPhase 4Toyos ClinicNCT01310127Written as Nepafenac
- Efficacy and Safety of PRO-155 Versus Nevanac in Post PhacoemulsificationCompletedPhase 2Laboratorios Sophia S.A de C.V.NCT01657266Written as Nevanac
Codes
What other systems call nepafenac · ClinicalTrials.gg INT004269
- MeSH (NLM) C414203nepafenacConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0J9L7J6V8CNEPAFENACConfirmed FDA, NLM, Wikidata
- RxNorm 298665Confirmed FDA, Wikidata
- Wikidata Q684379nepafenacConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66228NepafenacOne source FDA
- DrugBank DB06802One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C414203 | nepafenac | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0J9L7J6V8C | NEPAFENAC | Confirmed FDA, NLM, Wikidata |
| RxNorm | 298665 | — | Confirmed FDA, Wikidata |
| Wikidata | Q684379 | nepafenac | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66228 | Nepafenac | One source FDA |
| DrugBank | DB06802 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.